​

Pacira BioSciences (PCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PCRX Stock Forecast

Pacira BioSciences (PCRX) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $31.67, with a high of $36.50 and a low of $25.00. This represents a -13.04% decline from the last price of $36.42.

$20 $24 $28 $32 $36 $40 High: $36.5 Avg: $31.67 Low: $25 Last Closed Price: $36.42

PCRX Stock Rating

Pacira BioSciences stock's rating consensus is Hold, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (30.56%), 22 Hold (61.11%), 3 Sell (8.33%), and 0 Strong Sell (0.00%).

Hold
Total 36 0 3 22 11 Strong Sell Sell Hold Buy Strong Buy

PCRX Price Target Upside V Benchmarks

TypeNameUpside
StockPacira BioSciences-13.04%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks21.66%

Price Target Trends

1M3M12M
# Anlaysts379
Avg Price Target$34.67$31.29$30.89
Last Closing Price$36.42$36.42$36.42
Upside/Downside-4.81%-14.09%-15.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26143-19
Sep, 26132-17
Aug, 26122-16
Jul, 26122-16
Jun, 26132-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2026H.C. Wainwright$36.50$36.390.30%0.22%
Oct 09, 2026Truist Financial$36.50$36.390.30%0.22%
Oct 07, 2026Truist Financial$31.00$25.4122.00%-14.88%
Sep 23, 2026Oppenheimer$32.00$24.7029.55%-12.14%
Sep 09, 2026Leerink Partners$28.00$25.878.23%-23.12%
Aug 17, 2026Truist Financial$30.00$23.0030.43%-17.63%
Aug 05, 2026Douglas MiehmRBC Capital$25.00$27.62-9.49%-31.36%
May 01, 2026Needham$32.00$25.4925.54%-12.14%
Dec 08, 2025Barclays$27.00$24.4210.57%-25.86%
Feb 28, 2025Barclays$24.00$24.05-0.21%-34.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 09, 2026H.C. WainwrightBuyNeutraldowngrade
Oct 08, 2026OppenheimerOutperformPerformdowngrade
Oct 08, 2026JefferiesHoldMixeddowngrade
Oct 08, 2026JefferiesBuyHolddowngrade
Oct 08, 2026NeedhamBuyHolddowngrade
Sep 23, 2026OppenheimerOutperforminitialise
Aug 05, 2026RBC CapitalSector PerformSector Performhold
May 01, 2026NeedhamBuyBuyhold
Apr 13, 2026H.C. WainwrightBuyBuyhold
Dec 08, 2025BarclaysEqual-WeightNeutralinitialise

Financial Forecast

EPS Forecast

$-3 $-1 $1 $3 $5 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$0.35$0.91$-2.15$0.16---
Avg Forecast$2.91$2.63$2.91$3.13$3.29$3.72$4.23$4.66
High Forecast$3.30$3.01$3.02$3.39$3.92$5.35$6.29$5.89
Low Forecast$2.26$1.91$2.78$3.00$2.73$2.02$1.76$3.34
Surprise %-67.35%-86.69%-68.73%-168.69%-95.14%---

Revenue Forecast

$400M $530M $660M $790M $920M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$541.53M$666.82M$674.98M$700.97M$726.41M---
Avg Forecast$536.73M$666.80M$674.23M$696.42M$715.50M$757.03M$776.28M$836.93M
High Forecast$591.28M$740.69M$674.89M$777.84M$930.36M$757.05M$934.96M$1.01B
Low Forecast$443.84M$526.79M$673.31M$674.92M$564.23M$757.01M$607.29M$654.74M
Surprise %0.90%0.00%0.11%0.65%1.53%---

Net Income Forecast

$-100M $-10M $80M $170M $260M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$41.98M$15.91M$41.95M$-99.56M$26.71M---
Avg Forecast$38.43M$46.47M$41.95M$165.98M$172.79M$191.65M$209.41M$241.96M
High Forecast$48.01M$57.84M$52.23M$175.95M$203.60M$278.22M$327.18M$306.26M
Low Forecast$28.85M$35.09M$31.68M$156.01M$141.97M$105.08M$91.63M$173.49M
Surprise %9.24%-65.76%--159.98%-84.54%---

PCRX Forecast FAQ

Is Pacira BioSciences stock a buy?

Pacira BioSciences stock has a consensus rating of Hold, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 22 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Pacira BioSciences is a neutral investment for most analysts.

What is Pacira BioSciences's price target?

Pacira BioSciences's price target, set by 36 Wall Street analysts, averages $31.67 over the next 12 months. The price target range spans from $25 at the low end to $36.5 at the high end, suggesting a potential -13.04% change from the previous closing price of $36.42.

How does Pacira BioSciences stock forecast compare to its benchmarks?

Pacira BioSciences's stock forecast shows a -13.04% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (21.66%).

What is the breakdown of analyst ratings for Pacira BioSciences over the past three months?

  • October 2026: 11.11% Strong Buy, 44.44% Buy, 33.33% Hold, 0% Sell, 11.11% Strong Sell.
  • September 2026: 14.29% Strong Buy, 42.86% Buy, 28.57% Hold, 0% Sell, 14.29% Strong Sell.
  • August 2026: 16.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.

What is Pacira BioSciences’s EPS forecast?

Pacira BioSciences's average annual EPS forecast for its fiscal year ending in December 2026 is $3.72, marking a 2225.00% increase from the reported $0.16 in 2025. Estimates for the following years are $4.23 in 2027, and $4.66 in 2028.

What is Pacira BioSciences’s revenue forecast?

Pacira BioSciences's average annual revenue forecast for its fiscal year ending in December 2026 is $757.03M, reflecting a 4.21% increase from the reported $726.41M in 2025. The forecast for 2027 is $776.28M, and $836.93M for 2028.

What is Pacira BioSciences’s net income forecast?

Pacira BioSciences's net income forecast for the fiscal year ending in December 2026 stands at $191.65M, representing an 617.42% increase from the reported $26.71M in 2025. Projections indicate $209.41M in 2027, and $241.96M in 2028.